Biovica

Joint Bookrunner

Van Lanschot Kempen is pleased to announce that it acted as Joint Bookrunner to Biovica in its SEK 148m Fully Guaranteed Rights Issue

Transaction highlights

Rights Issue of 17,153,022 new shares at a subscription price of SEK 8.65 per share, generating gross proceeds of c. SEK 148m
Biovica intends to use the net proceeds to finance the initial launch of DiviTum®TKa in the US and Europe following the FDA 510(k) approval received in July 2022 for the treatment monitoring of metastatic breast cancer patients
The Rights Issue was fully subscribed for through a combination of subscription commitments, subscription with and without subscription rights and guarantee commitments from external investors
The transaction marks the third transaction where Van Lanschot Kempen has assisted a Life Sciences company with a so-called “Guaranteed Rights Issue”, thereby creating deal certainty for its clients even in challenging market circumstances, and underpinning our ambition to serve our clients with a wide variety of tailormade financing structures

Company description

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica’s assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: “Improved care for cancer patients.” Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B).

Background Van Lanschot Kempen Life Sciences & Healthcare

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank (EIB)
Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Capital Increase by Xbrane Biopharma
Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
Sole Global Coordinator in the SEK 200m financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva
Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
Financial adviser in the spin-out and capital increase of InnoSIGN
Co-Manager in the USD 806 million Capital Increase by argenx
Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
Co-Lead Manager in the USD 115 million Nasdaq IPO by IO Biotech
Lead manager in the USD 127 million Global Offering of Merus
Joint Global Coordinator and Joint Bookrunner in the €35.7 million Euronext IPO by MaaT Pharma

Please do not hesitate to contact us if you have further questions

Robin van Wijk

Mail Robin van Wijk

Pieter van der Meijden

Mail Pieter van der Meijden